{
    "organizations": [],
    "uuid": "6c5af59cb8fb04d4b38e749313fc3c2189fde784",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/20/pr-newswire-nordic-nanovector-asa-invitation-to-fourth-quarter-and-full-year-2017-results-presentation-and-webcast.html",
    "ord_in_thread": 0,
    "title": "Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "OSLO, Norway, Feb. 20, 2018 /PRNewswire/ --\nNordic Nanovector ASA (OSE: NANO) announces its fourth quarter and full year 2017 results on Tuesday, 27th of February 2018 .\nA presentation by Nordic Nanovector's senior management team will take place at 8:30 am CET at:\nThon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo\nMeeting Room: NYLAND\nThe presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media\nThe results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2017 from 7:00 am CET the same day.\nAbout Nordic Nanovector:\nNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019.\nNordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.\nFurther information about the company can be found at www.nordicnanovector.com\nFor further information, please contact:\nIR enquiries:\nMalene Brondberg, VP Investor Relations and Corporate Communications\nCell: +44-7561-431-762\nEmail: ir@nordicnanovector.com\nMedia Enquiries:\nMark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)\nTel: +44-207-638-9571\nEmail: nordicnanovector@citigatedewerogerson.com\nThis information was brought to you by Cision http://news.cision.com\nhttp://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-fourth-quarter-and-full-year-2017-results-presentation-and-webc,c2455781\nView original content: http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-fourth-quarter-and-full-year-2017-results-presentation-and-webcast-300600959.html\nSOURCE Nordic Nanovector",
    "published": "2018-02-20T09:12:00.000+02:00",
    "crawled": "2018-02-20T11:04:54.024+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "oslo",
        "norway",
        "nordic",
        "nanovector",
        "asa",
        "ose",
        "nano",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "result",
        "tuesday",
        "27th",
        "february",
        "presentation",
        "nordic",
        "nanovector",
        "senior",
        "management",
        "team",
        "take",
        "place",
        "cet",
        "thon",
        "hotel",
        "vika",
        "atrium",
        "munkedamsveien",
        "oslo",
        "meeting",
        "room",
        "nyland",
        "presentation",
        "recorded",
        "webcast",
        "available",
        "section",
        "investor",
        "medium",
        "result",
        "report",
        "presentation",
        "available",
        "section",
        "investor",
        "cet",
        "day",
        "nordic",
        "nanovector",
        "nordic",
        "nanovector",
        "committed",
        "develop",
        "deliver",
        "innovative",
        "therapy",
        "patient",
        "address",
        "major",
        "unmet",
        "medical",
        "need",
        "advance",
        "cancer",
        "care",
        "company",
        "aspires",
        "become",
        "leader",
        "development",
        "targeted",
        "therapy",
        "haematological",
        "cancer",
        "nordic",
        "nanovector",
        "lead",
        "candidate",
        "novel",
        "arc",
        "designed",
        "advance",
        "treatment",
        "lymphoma",
        "nhl",
        "nhl",
        "indication",
        "substantial",
        "unmet",
        "medical",
        "need",
        "representing",
        "growing",
        "market",
        "forecast",
        "worth",
        "nearly",
        "usd",
        "billion",
        "company",
        "aim",
        "rapidly",
        "develop",
        "alone",
        "combination",
        "therapy",
        "treatment",
        "major",
        "type",
        "nhl",
        "targeting",
        "first",
        "regulatory",
        "submission",
        "follicular",
        "lymphoma",
        "nordic",
        "nanovector",
        "intends",
        "retain",
        "marketing",
        "right",
        "actively",
        "participate",
        "commercialisation",
        "core",
        "market",
        "company",
        "also",
        "advancing",
        "pipeline",
        "arc",
        "immunotherapy",
        "multiple",
        "cancer",
        "indication",
        "information",
        "company",
        "found",
        "information",
        "please",
        "contact",
        "ir",
        "enquiry",
        "malene",
        "brondberg",
        "vp",
        "investor",
        "relation",
        "corporate",
        "communication",
        "cell",
        "email",
        "ir",
        "medium",
        "enquiry",
        "mark",
        "andrew",
        "citigate",
        "dewe",
        "rogerson",
        "tel",
        "email",
        "nordicnanovector",
        "information",
        "brought",
        "cision",
        "http",
        "http",
        "c2455781",
        "view",
        "original",
        "content",
        "http",
        "source",
        "nordic",
        "nanovector"
    ]
}